Stock Track | Insilico Medicine Soars 14.95% Intraday on Major $2.8 Billion AI Drug Discovery Deal with Lilly

Stock Track03-30

Insilico Medicine's stock surged 14.95% during intraday trading on Monday, following the announcement of a significant global research and development collaboration with pharmaceutical giant Eli Lilly and Company.

The collaboration centers on using Insilico's artificial intelligence platform to accelerate drug discovery and development across multiple therapeutic areas. As part of the deal, Insilico became eligible for a $120 million upfront payment, with potential milestone payments that could bring the total deal value to approximately $2.8 billion. The agreement also includes tiered royalties on future sales of any commercialized products.

The partnership grants Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral therapeutics currently in preclinical development for specific indications. This major deal represents a significant validation of Insilico's AI technology and provides a substantial near-term financial boost along with long-term revenue potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165154073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165154073","market":"us","top_or_hot":-1,"title":"Stock Track | Insilico Medicine Soars 14.95% Intraday on Major $2.8 Billion AI Drug Discovery Deal with Lilly","media":"Stock Track","content":"<p>Insilico Medicine's stock surged 14.95% during intraday trading on Monday, following the announcement of a significant global research and development collaboration with pharmaceutical giant Eli Lilly and Company.</p><p>The collaboration centers on using Insilico's artificial intelligence platform to accelerate drug discovery and development across multiple therapeutic areas. As part of the deal, Insilico became eligible for a $120 million upfront payment, with potential milestone payments that could bring the total deal value to approximately $2.8 billion. The agreement also includes tiered royalties on future sales of any commercialized products.</p><p>The partnership grants Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral therapeutics currently in preclinical development for specific indications. This major deal represents a significant validation of Insilico's AI technology and provides a substantial near-term financial boost along with long-term revenue potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insilico Medicine Soars 14.95% Intraday on Major $2.8 Billion AI Drug Discovery Deal with Lilly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insilico Medicine Soars 14.95% Intraday on Major $2.8 Billion AI Drug Discovery Deal with Lilly\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-30 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine's stock surged 14.95% during intraday trading on Monday, following the announcement of a significant global research and development collaboration with pharmaceutical giant Eli Lilly and Company.</p><p>The collaboration centers on using Insilico's artificial intelligence platform to accelerate drug discovery and development across multiple therapeutic areas. As part of the deal, Insilico became eligible for a $120 million upfront payment, with potential milestone payments that could bring the total deal value to approximately $2.8 billion. The agreement also includes tiered royalties on future sales of any commercialized products.</p><p>The partnership grants Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral therapeutics currently in preclinical development for specific indications. This major deal represents a significant validation of Insilico's AI technology and provides a substantial near-term financial boost along with long-term revenue potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1165154073","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165154073","pubTimestamp":1774834494,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insilico Medicine's stock surged 14.95% during intraday trading on Monday, following the announcement of a significant global research and development collaboration with pharmaceutical giant Eli...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"个股追踪|Insilico Medicine盘中大涨14.95%与礼来达成28亿美元AI药物发现重大交易","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine's stock surged 14.95% during intraday trading on Monday, following the announcement of a significant global research and development collaboration with pharmaceutical giant Eli Lilly and Company.The collaboration centers on using Insilico's artificial intelligence platform to accelerate drug discovery and development across multiple therapeutic areas. As part of the deal, Insilico became eligible for a $120 million upfront payment, with potential milestone payments that could bring the total deal value to approximately $2.8 billion. The agreement also includes tiered royalties on future sales of any commercialized products.The partnership grants Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of novel oral therapeutics currently in preclinical development for specific indications. This major deal represents a significant validation of Insilico's AI technology and provides a substantial near-term financial boost along with long-term revenue potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165154073","isCrawlerRequest":true}